The deal gives GlaxoSmithKline access to Tesaro’s ovarian cancer drug Zejula, within a new class of drugs known as PARP inhibitors. PARP inhibitors have increased survival rates for women with stubborn ovarian cancer.
“The acquisition of Tesaro will strengthen our pharmaceuticals business by accelerating the build of our oncology pipeline and commercial footprint, along with providing access to new scientific capabilities,” GlaxoSmithKline CEO Emma Walmsley told CNBC.
The deal, expected to close in the first quarter of 2019, was unanimously approved by Tesaro’s board. The cancer treatment company began exploring the possibility of a sale more than a year ago, according to The Wall Street Journal.
The deal positions GlaxoSmithKline deeper into the highly competitive PARP-inhibitor cancer market. It likely will race market-leading PARP-inhibitor manufacturer AstraZeneca to test the inhibitors on other cancer types, according to WSJ.
Centerview Partners provided financial advice to Tesaro.
More articles on pharmacy:
Teva launches generic EpiPen for $300
Bayer considers sale of consumer health brands
Unilever wants to buy GlaxoSmithKline’s nutrition business: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.